Johnson & Johnson image shows a single-dose Covid-19 vaccine being developed by the company. Photo / APA late-stage study of Johnson & Johnson's Covid-19 vaccine candidate has been paused while the company investigates whether a study participant's "unexplained illness" is related to the shot. "Following our guidelines, the participant's illness is being reviewed and evaluated by the Ensemble independent Data Safety Monitoring Board as well as our internal clinical and safety physicians," Johnson & Johnson said. Johnson & Johnson last week sealed a deal with the European Union for 200 million doses of its vaccine "following approval or authorisation from regulators", with the option of another 200 million doses. Johnson & Johnson was aiming to enrol 60,000 volunteers to prove if its single-dose approach is safe and protects against the coronavirus.

Source: New Zealand Herald October 13, 2020 03:22 UTC